Immudyne Announces Successful National Launch of Shapiro MD Hair Loss Product Line
June 07 2017 - 8:00AM
ImmuDyne, Inc. (OTCQB:IMMD) (“Immudyne” or the “Company”), a leader
in the development and marketing of OTC healthcare products, is
pleased to announce a successful national launch of our patented
Shapiro MD product line.
Within the first several weeks of the product’s launch on
Facebook, Immudyne sold all available inventory. Our entire team
and supply chain partners have been working diligently to increase
production and inventory levels for the product, and we’re pleased
to report that as of today we have sufficient inventory levels to
considerably scale the Shapiro MD business.
“Although we had and continue to have big expectations for the
Shapiro MD line, the initial success of our marketing efforts
exceeded everyone’s expectations,” stated Justin Schreiber,
President of Immudyne PR. “I believe that the success of this
product launch reinforces Immudyne PR’s business model of
in-licensing high quality consumer products in large addressable
markets that can be scaled through online marketing channels such
as Facebook, Google and Amazon.”
The Shapiro MD product line is the result of 15 years of
research and development by thought-leading dermatologists Dr.
Steven Shapiro and Dr. Michael Borenstein. It is protected by
two U.S. patents and is the only product in the hair loss vertical
that contains what we believe are the 3 most powerful,
naturally-occurring dihydrotestosterone (DHT) blocking
ingredients. DHT is widely believed to be the main culprit of
balding/hair-loss.
In addition to the Shampoo and Conditioner, Immudyne PR has
formulated a once-daily leave in foam and is finalizing the
formulation of a nutritional supplement. We believe both products
will be a strong addition to the product line and should be
available within the next 90 days.
“The amount of inbound inquiries we’ve received on Shapiro MD
within the first several weeks of launch is off-the-charts,” stated
Mark McLaughlin, Chief Executive Officer of Immudyne. “We’re
very excited about the potential of the line and are now
laser-focused on scaling inventory levels and optimizing our
infrastructure to permit profitable revenue growth around the
world.”
The global alopecia (hair loss) market is expected to reach USD
11.8 Billion by 2024 according to a recent report published by
independent research firm, Grand View Research, Inc.
For more information on Shapiro MD or to purchase the product,
please visit www.shapiromd.com.
About lmmuDyne
lmmuDyne, Inc. (the "Company") is a health and wellness company
that develops, manufactures, and markets innovative consumer
products. Immudyne manufactures and markets a proprietary and
patent protected Yeast Beta Glucan that has been shown in thousands
of clinical studies to support and regulate the human immune
system. It has broad applications in skincare and as an
immune support supplement. Immudyne PR, a majority owned
subsidiary of ImmuDyne, Inc., is the digital marketing arm of
Immudyne and is currently focused on marketing products for thicker
and fuller hair (Shapiro MD) and a skincare line containing
Immudyne’s proprietary Yeast Beta Glucan ingredient (Inate
MD). All of lmmuDyne's intellectual property is protected by
patents and/or trade secrets. Additional information can be found
on the web at www.immudyne.com.
Forward-Looking StatementsCautionary language regarding
Forward-Looking Statements Safe Harbor Act Disclaimer: Forward
looking statements in this release are made pursuant to the Safe
Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. Certain statements in this press release, including
projections with respect to lmmuDyne's results of operations, may
contain words such as "anticipates," "believes," "could,"
"estimates," "expects," "intends," "may," "projects,"
"plans," "targets" and other similar language and are
considered forward-looking statements. These statements are based
on management's current expectations, estimates, and forecasts.
These forward-looking statements are subject to important
assumptions, risks and uncertainties, which are difficult to
predict and therefore the actual results may be materially
different from those discussed.
Contact:
ImmuDyne, Inc.
Mark McLaughlin: +1-914-714-8901